NCT06327295

A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis

Name: Clinical Trial NCT06327295
Creator: AmtixBio Co., Ltd.
Keywords: Onychomycosis, ATB1651-102- Cohort 1, Phase 2, drug, clinical trial, New Zealand

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the

AmtixBio Co., Ltd.·Phase 2·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Onychomycosis
Drug/Device/Intervention: ATB1651-102- Cohort 1
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: AmtixBio Co., Ltd.
Location: Christchurch, New Zealand

Timeline & enrollment

Phase: Phase 2
Start date: Mar 30, 2024
End date: Jan 30, 2026
Enrollment: 120 participants

Primary outcome

To evaluate the complete cure rate with topical ATB1651 3% and ATB1651 5% in participants with mild to moderate onychomycosis.

Summary

The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in participants with mild to moderate onychomycosis

ICD-10 classifications

OnychogryphosisChromomycosis, unspecifiedOnycholysisActinomycosisBlastomycosis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06327295
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06327295 through Pure Global AI's free database. This Phase 2 trial is sponsored by AmtixBio Co., Ltd. and is currently Not yet recruiting. The study focuses on Onychomycosis. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.